Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Shenzhen Hightide Biopharmaceutical Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed among 4 examiners and 3 art units, showing that the portfolio reaches several examination assignments rather than a single review channel.
BRAUN, MADELINE E is the busiest examiner, with 1 pending matter. No examiner accounts for more than that identified share of the pending record, so prosecution planning should preserve matter-specific analysis across the examiner group. The art-unit spread also supports checking whether claim interpretation, prior-art searches, and response timing differ by assignment.
For counsel, the principal management issue is coordination. Each response should remain tailored to its assigned examiner and art unit, while portfolio-level tracking should identify recurring objections across the biotechnology matters without assuming that one examiner's approach governs the others.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| BOECKELMAN, JACOB A | 1 | 34.9% | +46.5% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18134495 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | WILLIS, DOUGLAS M | 42d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18904564 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | BRAUN, MADELINE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18387769 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | BOECKELMAN, JACOB A | 5d overdue |
| 18202033 | COMPOSITIONS OF BERBERINE URSODEOXYCHOLATE AND METHODS THEREOF FOR TREATING PRIMARY SCLEROSING CHOLANGITIS | BARSKY, JARED | 15d |
| 18134495 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | WILLIS, DOUGLAS M | 42d |
| 18904564 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | BRAUN, MADELINE E | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1655 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18904564 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | BRAUN, MADELINE E | 1624 | §102§112Other | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18387769 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | BOECKELMAN, JACOB A | 1655 | §103§112DP | Final Rejection | 5d overdue | Pending | Nov 07, 2023 |
| 18202033 | COMPOSITIONS OF BERBERINE URSODEOXYCHOLATE AND METHODS THEREOF FOR TREATING PRIMARY SCLEROSING CHOLANGITIS | BARSKY, JARED | 1628 | §103Other | Final Rejection | 15d | Pending | May 25, 2023 |
| 18134495 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | 42d | Pending | Apr 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenzhen Hightide Biopharmaceutical Ltd. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Madeline E Braun has the most, with 1 of Shenzhen Hightide Biopharmaceutical Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
